PDCD1 and lymphoma: Here, we aimed to review recent information on the predictive and prognostic value of laboratory methods and biomarkers for clinical follow-up of patients with leukemia or lymphoma who were treated with ICBs, particularly with anti-CTLA-4 and anti-PD-1/PD-L1 antibodies, the most widely used ICIs.